Press Releases Dec 14, 2017 • 7:01 AM EST Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors Nov 15, 2017 • 7:35 AM EST Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update Oct 11, 2017 • 8:05 AM EDT Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference Sep 19, 2017 • 9:20 AM EDT Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Sep 12, 2017 • 7:30 AM EDT Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 Aug 8, 2017 • 6:05 AM EDT Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 Aug 3, 2017 • 8:05 AM EDT Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference Aug 1, 2017 • 8:30 AM EDT Matinas BioPharma to Host Quarterly Update Conference Call Jun 26, 2017 • 6:05 AM EDT Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis Jun 3, 2017 • 4:00 PM EDT Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis << Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ...15 | Next >>
